Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 107.14 percent decrease over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $3.824 million which missed the analyst consensus estimate of $6.447 million by 40.69 percent. This is a 3.41 percent increase over sales of $3.698 million the same period last year.